الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 78 |  |  |
| | | from | 78 | | |
Abstract
In the period from May 2018 to April 2019, 300 patients with STEMI treated with primary PCI were prospectively enrolled in this multi-center observational study in 3 PCI-capable centers in Cairo city, Egypt. STEMI was defined as follows: ongoing ischemic symptoms (within 12 h) together with ST-segment elevation (measured at the J-point) in at least two contiguous leads of 2.5 mm in men < 40 years, 2 mm in men > 40 years, or 1.5 mm in women in leads V2–V3 and/or 1 mm in the other leads [in the absence of left ventricular (LV) hypertrophy or left bundle branch block (LBBB)] (Ibanez, et al. 2017). We excluded patients with previous history of documented myocardial infarction, patients presenting in cardiogenic shock, those with other concomitant valvular or structural heart diseases and those patients with advanced illnesses that limit life expectancy such as terminal cancer and advanced chronic kidney or liver diseases.Enrolled patients were categorized into 3 groups based on the mode of presentation to the centers participating in the study:group A: Self-presenting to the ED.group B: Transferred by ambulance to the ED.group C: Patients who were transferred directly to CCL (bypassing the ED as possible) after the team has been alerted and pre-activated through an ECG image sent (using WhatsApp) on their route from non-PCI-capable to the participating PCI-capable centers. The primary endpoints were between-group differences in total ischemic time (defined as time from symptom onset to balloon inflation) and D2B time (defined as time from arrival to PCI-capable center to balloon inflation).